OPTIMIZER Smart
OPTIMIZER Smart Post-Approval Study

Investigator: Jared Green, DO

The purpose of this post approval study (PAS) is to evaluate the safety of the long-term use of the OPTIMIZER Smart device and Cardiac Contractility Modulation therapy on the quality of life and heart failure symptoms for patients who remain symptomatic despite optimized guideline directed heart failure medications.

Learn more about the OPTIMIZER Smart study.

View on ClinicalTrials.gov, Impulse-Dynamics, and FDA.gov or call the Clinical Trials Office at 484-628-8585 for more information.

AIM HIGHer, OPTIMIZER Smart Mini System

Investigator: Jared Green, DO

The purpose of the Optimizer Smart Mini System is indicated for the improvement of health status, functional capacity, heart failure related adverse events, and cardiovascular mortality in patients with symptomatic heart failure with a left ventricular ejection fraction ≥40 and ≤ 60%. While evaluating the efficacy and safety of Cardiac Contractility Modulation (CCM) therapy in patients with symptomatic HF40-60 (HF with LVEF 40-60%). 

Learn more about the AIM HIGHer study.
 
View on Clinicaltrials.org, Impulse-Dynamics, or call the Clinical Trials Office at 484-628-8585 for more information.